Related Experiment Video

Updated: Jun 2, 2026

Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins
08:12

Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins

Published on: January 8, 2018

Protein modification systems as cancer biomarkers and therapeutic targets

Li Gao1, Yueqin He1, Kexin Wang1

  • 1National Clinical Research Center for Geriatrics and Department of Laboratory Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Wuhou, Chengdu 610041, China.

Precision Clinical Medicine
|June 1, 2026
PubMed

Insights

Protein post-translational modifications (PTMs) are crucial for cell functions and are altered in cancer, impacting disease progression and treatment. This review covers PTM biomarkers and therapeutic targets in cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Protein post-translational modifications (PTMs) regulate fundamental cellular processes like signal transduction, metabolism, and proteostasis.
  • Dysregulated PTM networks are a hallmark of cancer, influencing sustained proliferation, immune evasion, and therapeutic resistance.

Purpose of the Study:

  • To review biomarkers and therapeutic targets associated with altered PTM regulatory pathways in cancer.
  • To highlight the role of PTMs in shaping cancer hallmarks and disease progression.

Main Methods:

  • Comprehensive literature review of PTMs in cancer.
  • Analysis of recent advances in proteomic technologies for PTM mapping.
  • Identification of PTM signatures related to tumor characteristics and treatment.

Main Results:

  • PTMs, including acetylation, lactylation, methylation, phosphorylation, ubiquitination, and glycosylation, are significantly rewired in cancer.
  • Altered PTM enzyme levels and crosstalk contribute to cancer hallmarks.
  • PTM signatures can aid in tumor subtyping, predicting progression, and response to therapy.

Conclusions:

  • Dysregulated PTMs represent critical areas for cancer biomarker and therapeutic target discovery.
  • Understanding PTM networks offers new avenues for cancer treatment strategies.
Keywords:
biomarkercancerprecision medicineprotein modificationstherapeutic target

More Related Videos

Histone Modification Screening using Liquid Chromatography, Trapped Ion Mobility Spectrometry, and Time-Of-Flight Mass Spectrometry05:52

Histone Modification Screening using Liquid Chromatography, Trapped Ion Mobility Spectrometry, and Time-Of-Flight Mass Spectrometry

Published on: January 12, 2024

SUMO-Binding Entities (SUBEs) as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer08:29

SUMO-Binding Entities (SUBEs) as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer

Published on: November 1, 2019

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: